Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2019

Open Access 01-12-2019 | Obesity | Original investigation

Renal glucosuria is associated with lower body weight and lower rates of elevated systolic blood pressure: results of a nationwide cross-sectional study of 2.5 million adolescents

Authors: Boris Fishman, Gadi Shlomai, Gilad Twig, Estela Derazne, Alexander Tenenbaum, Enrique Z. Fisman, Adi Leiba, Ehud Grossman

Published in: Cardiovascular Diabetology | Issue 1/2019

Login to get access

Abstract

Background

Gene coding mutations found in sodium glucose co-transporters (SGLTs) are known to cause renal glucosuria. SGLT2 inhibitors have recently been shown to be effective hypoglycemic agents as well as possessing cardiovascular and renal protective properties. These beneficial effects have to some extent, been attributed to weight loss and reduced blood pressure. The aim of the current study was to evaluate the prevalence of renal glucosuria amongst a large cohort of Israeli adolescents and to investigate whether renal glucosuria is associated with lower body weight and lower blood pressure values.

Methods

Medical and socio-demographic data were collected from the Israeli Defense Force’s conscription center’s database. A cross-sectional study to evaluate the association between conscripts diagnosed as overweight [BMI percentiles of ≥ 85 and < 95 and obesity (≥ 95 BMI percentile)] and afflicted with renal glucosuria was conducted. In addition, we assessed the association of renal glucosuria with elevated diastolic and systolic blood pressure. Multinomial regression models were used.

Results

The final study cohort comprised 2,506,830 conscripts of whom 1108 (0.044%) were diagnosed with renal glucosuria, unrelated to diabetes mellitus, with males twice as affected compared to females. The adjusted odds ratio for overweight and obesity was 0.66 (95% CI 0.50–0.87) and 0.62 (95% CI 0.43–0.88), respectively. Adolescents afflicted with renal glucosuria were also less likely to have an elevated systolic blood pressure of 130–139 mmHg with an adjusted odds ratio of 0.74 (95% CI 0.60–0.90).

Conclusions

Renal glucosuria is associated with lower body weight and obesity as well as with lower rates of elevated systolic blood pressure.
Appendix
Available only for authorised users
Literature
21.
23.
go back to reference Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020–31. https://doi.org/10.1210/jc.2011-2260.CrossRefPubMed Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020–31. https://​doi.​org/​10.​1210/​jc.​2011-2260.CrossRefPubMed
24.
26.
go back to reference Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37(7):1815–23. https://doi.org/10.2337/dc13-3055.CrossRefPubMed Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37(7):1815–23. https://​doi.​org/​10.​2337/​dc13-3055.CrossRefPubMed
28.
go back to reference Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16(2):147–58. https://doi.org/10.1111/dom.12188.CrossRefPubMed Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16(2):147–58. https://​doi.​org/​10.​1111/​dom.​12188.CrossRefPubMed
35.
go back to reference Kouidi E, Fahadidou-Tsiligiroglou A, Tassoulas E, Deligiannis A, Coats A. White coat hypertension detected during screening of male adolescent athletes. Am J Hypertens. 1999;12(2 Pt 1):223–6.CrossRef Kouidi E, Fahadidou-Tsiligiroglou A, Tassoulas E, Deligiannis A, Coats A. White coat hypertension detected during screening of male adolescent athletes. Am J Hypertens. 1999;12(2 Pt 1):223–6.CrossRef
Metadata
Title
Renal glucosuria is associated with lower body weight and lower rates of elevated systolic blood pressure: results of a nationwide cross-sectional study of 2.5 million adolescents
Authors
Boris Fishman
Gadi Shlomai
Gilad Twig
Estela Derazne
Alexander Tenenbaum
Enrique Z. Fisman
Adi Leiba
Ehud Grossman
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2019
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-019-0929-7

Other articles of this Issue 1/2019

Cardiovascular Diabetology 1/2019 Go to the issue